Business Wire

NY-IWBI

8.6.2020 17:03:03 CEST | Business Wire | Press release

Share
International WELL Building Institute Launches WELL Health-Safety Rating for all Building and Facility Types

The International WELL Building Institute (IWBI) announced today the launch of the WELL Health-Safety Rating for all building and facility types, an evidence-based, third-party verified rating focusing on operational policies, maintenance protocols and design strategies to address a post COVID-19 environment. The WELL Health-Safety Rating is one of the earliest outcomes of IWBI’s Task Force on COVID-19 , a group of nearly 600 public health experts, virologists, government officials, academics, business leaders, architects, designers, building scientists and real estate professionals, which was established in late March to help guide IWBI’s response to the pandemic.

The WELL Health-Safety Rating provides a centralized source and governing body to validate efforts made by owners and operators. It leverages insights drawn from the IWBI COVID-19 Task Force, in addition to guidance on the spread of COVID-19 and other respiratory infections developed by the Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO), the Department of Health and Human Services pursuant to the Occupational Safety and Health Act (OSHA), the National Institutes of Health (NIH), and leading academic and research institutions, as well as core principles already established by IWBI’s WELL Building Standard. Participation in the program requires submission of policies, protocols and strategies for third-party document review and annual verification.

“The WELL Health-Safety Rating is a sign of confidence that measures have been enacted to help support the health and safety of people entering spaces of all kinds, and that those measures have been mapped to scientific evidence and verified through a third-party review process,” said Rick Fedrizzi, chairman & CEO of IWBI. “By drawing on the proven strategies in WELL, we’re working from the best science available and that’s more important than it’s ever been.”

The WELL Health-Safety Rating will accept registrations in June from all types of buildings and facility typologies, including offices, restaurants, hotels, retail establishments, manufacturing plants, warehouses, sports stadiums, arenas, theaters and other entertainment venues, schools, multi-family housing, and many others. Current WELL-registered projects and WELL Portfolio participants can earn the WELL Health-Safety Rating as part of their already established certification efforts.

“Our buildings and the people who tend them are our first line of defense for keeping us safe and healthy,” said Rachel Gutter, president of IWBI, “and the current pandemic has confirmed that health is a material economic consideration of the first order. These two simple truths stand at the nexus of our work to date and will, along with the hard evidence that is mounting, inform all our decisions about the critical need for better buildings, more vibrant communities and stronger organizations going forward.”

The WELL Health-Safety Rating is the first of many anticipated outcomes informed by the work of the IWBI COVID-19 Task Force that will be introduced in the coming months. Members of the Task Force include 17th Surgeon General of the United States Dr. Richard Carmona, former Robert Wood Johnson Foundation President and CEO Dr. Risa Lavizzo-Mourey, UCLA’s Dr. Jonathan Fielding, Harvard School of Public Health’s Joseph Allen, and environmental scientist Allen Hershkowitz Ph.D., among others.

“The Task Force has received overwhelming support and input from all over the world,” said Dr. Richard Carmona, 17th Surgeon General of the United States. “People are learning that buildings themselves can be powerful vehicles for protecting and improving public health. All of us individually have a responsibility to the collective whole to use every tool, including our buildings and our sense of community, to keep ourselves and those we care about safe.”

“The impacts of the virus have been many, but not the least is the anxiety of uncertainty about where people feel safe,” said Despina Katsikakis, Head of Occupier Business Performance at Cushman Wakefield and member of IWBI’s COVID-19 Task Force. “Achieving this new WELL Health-Safety Rating is a great way to increase confidence that evidence-based steps to do the right thing have been taken to keep health front and center as the economy reopens.”

Recently, IWBI released an interim Strategies from the WELL Building Standard to Support in the Fight Against COVID-19, another key outcome of the Task Force. Grounded in the foundation of WELL, these evidence-based strategies provide an actionable framework for organizations and communities as they advance a safer and healthier future. IWBI is expanding these strategies into Guidelines for Preparedness and Prevention, Resilience and Recovery in relation to COVID-19 and other respiratory infections. The Guidelines will provide insight into how the current strategies have evolved, as well as indicate areas where further work is required.

Since its inception, IWBI has been driving forward the convergence of building science and health science. Registrations under the WELL Building Standard, the premier standard for healthy real estate, have already surpassed 550 million square feet across 62 countries. The WELL Building movement has been further amplified by over 11,000 WELL Accredited Professionals (APs) and registrants across the globe.

Gutter noted that upon achieving the designation, IWBI will issue the project a WELL Health-Safety Rating seal. Register interest in the WELL Health-Safety Rating here .

About the International WELL Building Institute

The International WELL Building Institute (IWBI) is leading the global movement to transform our buildings, communities and organizations in ways that help people thrive. The WELL v2 pilot is the latest version of its popular WELL Building Standard (WELL), and the WELL Community Standard pilot is a district scale rating system that sets a new global benchmark for healthy communities. WELL is focused exclusively on the ways that buildings and communities, and everything in them, can improve our comfort, drive better choices, and generally enhance, not compromise, our health and wellness. IWBI mobilizes the wellness community through management of the WELL AP credential, the pursuit of applicable research, the development of educational resources, and advocacy for policies that promote health and wellness for everyone, everywhere. For more information about IWBI and WELL, visit us here .

International WELL Building Institute, IWBI, the WELL Building Standard, WELL v2, WELL Certified, WELL AP, WELL, WELL Portfolio, The WELL Conference, the WELL Community Standard, WELL Workforce, WELL Health-Safety Rating and others, and their related logos are trademarks or certification marks of International WELL Building Institute pbc in the United States and other countries.

Social Media:

https://facebook.com/wellbuildinginstitute/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse

Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release

Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye